



Market Announcement

8 January 2025

Arovella Therapeutics Limited (ASX: ALA) – Trading Halt

Description

The securities of Arovella Therapeutics Limited ('ALA') will be placed in trading halt at the request of ALA, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 10 January 2025 or when the announcement is released to the market.

Issued by

ASX Compliance

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



8 January 2025

Melissa Kostopoulos
Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
Level 4, Rialto North Tower
525 Collins Street
Melbourne VIC 3000

BY EMAIL to: melissa.kostopoulos@asx.com.au & tradinghaltsmelbourne@asx.com.au

Dear Melissa

REQUEST FOR TRADING HALT

Arovella Therapeutics Limited (ASX: ALA) (the "Company") requests that a trading halt be granted by the Australian Securities Exchange ("ASX") with respect to its ordinary shares to apply from the commencement of trading today Wednesday 8 January 2025 until the commencement of trading Friday 10 January 2025.

As required by ASX Listing Rule 17.1, the Company provides the following information:

1. The Company requests a trading halt immediately, pending the release of an announcement regarding a substantial investment into the Company, capital raise and subsequent issue of securities.
2. The Company requests that the trading halt remain in place until the earlier of the commencement of trade on 10 January 2025 or the release of an announcement by the Company in respect of the capital raise; and
3. The Company is not aware of any reason why the trading halt should not be granted, or any other information necessary to inform the market about the trading halt.

This request has been authorised by the Board of Arovella Therapeutics Limited.

Kind regards

A handwritten signature in black ink, appearing to be "Tim Luscombe", written over a horizontal line.

Tim Luscombe
Company Secretary & CFO
Arovella Therapeutics Limited